DMID 25-1106

Study Details

Full Title

A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults

Principal Investigator

Emmanuel
Walter

Protocol Number

PRO00120019

Phase

I

Enrollment Status

Open to Enrollment